NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Aurinia Pharmaceuticals Inc. AUPH
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$283.1M
▲ 20.4% vs FY2024
EPS · FY25
$2.07
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
59.9%
Net margin · FY25
101.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 283.1M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
101 cents of every revenue dollar became profit this year.
Per share
USD 2.07
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
59.9%
Return on equity, FY2025
ROE
Operating margin37.1%
Net margin101.5%
Return on assets44.1%
Each USD of equity produced 60 cents of profit this year.
Returned to shareholders
USD 97.4M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 97.4M
Share of profit33.9%
Consecutive raises—
USD 97.4M in buybacks — 34% of the year's profit went back to shareholders.
Growth
+41.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+28.3%
+41.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.13B
Shares outstanding, FY2025
Change, 5 years+4.4%
Change, 10 years—
The share count grew 4% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 751.6M
total assets, end of FY2025
Total assetsUSD 751.6M
EquityUSD 581.3M
CashUSD 80.2M
Current ratio5.25×
Equity funds 77% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.3
0.2
0.2
0.1
0.0
0.1
0.0
0.0
Operating income $B
0.1
−0.0
−0.1
−0.1
−0.2
−0.1
−0.1
−0.1
EBITDA $B
0.1
0.0
−0.1
−0.1
−0.2
−0.1
−0.1
−0.1
Income tax $B
−0.2
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
Net income $B
0.3
0.0
−0.1
−0.1
−0.2
−0.1
−0.1
−0.1
EPS, diluted $
2.07
0.04
−0.54
−0.76
−1.40
−0.87
−0.95
−0.63
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
59.9
1.5
−19.9
−24.5
−40.8
−29.1
−40.7
−39.1
Shares out B
0.13
0.14
0.14
0.14
0.14
0.13
0.11
0.09
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
22 of 22
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed